Fig. 6
The tumour immune microenvironment revealed by RNA sequencing results of tumour tissues in different treatment groups. A The immune cell infiltration analysis results of tumour tissues from the OH2 combined anti-SIRPα antibody group, OH2 group, and control group by GSVA. B The scoring results of immune cells (macrophages, DCs, Th1 cells, Th2 cells, T cells, CD8 T cells, NK CD56bright cells, and cytotoxic cells) of tumour tissues from the OH2 combined anti-SIRPα antibody group, OH2 group, and control group by GSVA. C The immune-related signalling pathways of tumour tissues from the OH2 combined anti-SIRPα antibody group, OH2 group, and control group by GSVA. D The scoring results of immune-related signalling pathways (interferon, NK cell activity, cytotoxicity, T cell priming, and activation, immune cell localization to tumours, cytokine, and chemokine signalling) of tumour tissues from the OH2 combined anti-SIRPα antibody group, OH2 group, and control group by GSVA. E GO analysis of differentially expressed genes in the control group and the OH2 combined anti-SIRPα antibody group. F GO analysis of differentially expressed genes in the OH2 group and the OH2 combined anti-SIRPα antibody group. G The expression level of M1-related cytokines in the OH2 group, OH2 combined with anti-SIRPα antibody group and control group. H The expression levels of T cell-related cytokines in the OH2 group, and OH2 combined with the anti-SIRPα antibody group and the control group. I The expression level of NK-related cytokines in the OH2 group, OH2 combined with anti-SIRPα antibody group and control group. An unpaired Student’s t test was used to analyse the significance of the difference between the two groups. ns, no significant differences, *, p<0.05, **, p<0.01, ***, p<0.001, ****, p<0.0001. The colour represents the value of the expression level of the gene in RNA sequencing. OH2 + SIRPα represents the OH2 combined with the anti-SIRPα antibody group